Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 106 AL 120

Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients

Domínguez RO, Marschoff ER, González SE, Repetto MG, Serra JA.

Diabetes Res Clin Pract. 2012 Oct;98(1):68-74. doi: 10.1016/j.diabres.2012.05.013. Epub 2012 Jun 2.

Novel disease-modifying therapies for Alzheimer's disease

Jiang T, Yu JT, Tan L.

J Alzheimers Dis. 2012;31(3):475-92. doi: 10.3233/JAD-2012-120640.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. doi: 10.2174/138945012802009026.

Pleiotropic protective effects of phytochemicals in Alzheimer's disease

Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G.

Oxid Med Cell Longev. 2012;2012:386527. doi: 10.1155/2012/386527. Epub 2012 May 28.

The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation

Anand A, Banik A, Thakur K, Masters CL.

Curr Alzheimer Res. 2012 Nov;9(9):1010-29. doi: 10.2174/156720512803569055.

Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria

Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP.

Mol Neurobiol. 2012 Aug;46(1):161-78. doi: 10.1007/s12035-012-8282-9. Epub 2012 Jun 17.

Copper and oxidative stress in the pathogenesis of Alzheimer's disease

Eskici G, Axelsen PH.

Biochemistry. 2012 Aug 14;51(32):6289-311. doi: 10.1021/bi3006169. Epub 2012 Jul 31.

Colombia at the centre of preclinical AD research

Lancet Neurol. 2012 Jul;11(7):567. doi: 10.1016/S1474-4422(12)70144-8.

γ-Secretase modulator in Alzheimer's disease: shifting the end

Xia W, Wong ST, Hanlon E, Morin P.

J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751.

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia

Allegri RF, Guekht A.

Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X.

The link between altered cholesterol metabolism and Alzheimer's disease

Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G.

Ann N Y Acad Sci. 2012 Jul;1259:54-64. doi: 10.1111/j.1749-6632.2012.06513.x.

Neurotoxicity of amyloid β-protein: synaptic and network dysfunction

Mucke L, Selkoe DJ.

Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006338. doi: 10.1101/cshperspect.a006338.

Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial

Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ.

J Alzheimers Dis. 2012;31(1):225-36. doi: 10.3233/JAD-2012-121189.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias